SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

07 Aug 2023 Evaluate
The sales figure stood at Rs. 4112.87 millions for the June 2023 quarter. The mentioned figure indicates a growth of about 25.10% as compared to Rs. 3287.60 millions during the year-ago period.A humble growth in net profit of 15.85% reported in the quarter ended June 2023 to Rs. 1107.42  millions from Rs. 955.91 millions.Operating Profit saw a handsome growth to 1595.27 millions from 1295.59 millions in the quarter ended June 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 4112.87 3287.60 25.10 4112.87 3287.60 25.10 13307.25 12157.30 9.46
Other Income 40.26 33.72 19.40 40.26 33.72 19.40 172.64 289.89 -40.45
PBIDT 1595.27 1295.59 23.13 1595.27 1295.59 23.13 5223.78 5129.84 1.83
Interest 68.42 72.26 -5.31 68.42 72.26 -5.31 208.10 29.91 595.75
PBDT 1526.85 1223.33 24.81 1526.85 1223.33 24.81 5015.68 5099.93 -1.65
Depreciation 201.63 149.72 34.67 201.63 149.72 34.67 646.57 514.55 25.66
PBT 1325.22 1073.61 23.44 1325.22 1073.61 23.44 4369.11 4585.38 -4.72
TAX 217.80 117.70 85.05 217.80 117.70 85.05 389.03 413.46 -5.91
Deferred Tax 0.44 -76.24 -100.58 0.44 -76.24 -100.58 -375.93 -388.26 -3.18
PAT 1107.42 955.91 15.85 1107.42 955.91 15.85 3980.08 4171.92 -4.60
Equity 135.99 135.97 0.01 135.99 135.97 0.01 135.99 135.93 0.04
PBIDTM(%) 38.79 39.41 -1.58 38.79 39.41 -1.58 39.26 42.20 -6.97

Eris Lifesciences Share Price

1446.50 -18.90 (-1.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×